• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by CytoMed Therapeutics Limited

    5/16/25 6:30:26 AM ET
    $GDTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GDTC alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of May 2025

     

    Commission File Number: 001-41677

     

    CytoMed Therapeutics Limited

    (Exact name of registrant as specified in its charter)

     

    1 Commonwealth Lane

    #08-22

    Singapore 149544

    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    INFORMATION CONTAINED IN THIS FORM 6-K REPORT

     

    In connection with the annual general meeting of shareholders of CytoMed Therapeutics Limited (the “Company”), attached hereto and incorporated by reference herein are Notice of Annual General Meeting and Proxy Statement and Form of Proxy Card.

     

    2

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    99.1   Notice of Annual Shareholder Meeting and Proxy Statement
    99.2   Form of Proxy Card

     

    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      CytoMed Therapeutics Limited
       
    Date: May 16, 2025 By: /s/ CHOO Chee Kong
      Name: CHOO Chee Kong
      Title: Chairman and Director

     

    4

     

    Get the next $GDTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GDTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GDTC
    Financials

    Live finance-specific insights

    See more
    • CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

      SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies without engaging in separate activities such as contract manufacturing, contract research, medical device development, or diagnostics, today announced its full-year ended December 31, 2024 financial results and provided clinical and corporate updates. We intend to be among the early pioneers of cellular immunotherapy treatment modalities to serve the ASEAN region and North Asia with

      4/28/25 4:05:00 PM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

      SINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers including blood and solid cancers has obtained full approval for its first-in-human Phase I clinical trial ("ANGELICA Trial") using its patented allogeneic chimeric antigen receptor T cell ("CAR-T cell") against several blood and solid tumors in collaboration with the National University Hospital ("NUH") of Singapore. The ANGELICA Trial is co-supported by the Singapore Minist

      10/7/24 7:00:00 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

      Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived, cell-based allogeneic immunotherapies for the treatment of a broad range of cancers including blood and solid tumors, today announced six months ended June 30, 2024 financial results and provided clinical and corporate updates. "We are committed to advancing our "off-the-shelf" allogeneic c

      9/30/24 7:00:00 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GDTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CytoMed Therapeutics Limited (Amendment)

      SC 13G/A - CytoMed Therapeutics Ltd (0001873093) (Subject)

      5/23/24 6:10:52 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GDTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

      SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies without engaging in separate activities such as contract manufacturing, contract research, medical device development, or diagnostics, today announced its full-year ended December 31, 2024 financial results and provided clinical and corporate updates. We intend to be among the early pioneers of cellular immunotherapy treatment modalities to serve the ASEAN region and North Asia with

      4/28/25 4:05:00 PM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders

      SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board of Directors (the "Board") as it welcomes the new year ahead of its full-year audited results announcement due by end-April, the full text of which is provided below. All shareholders of CytoMed are encouraged to read. Dear Shareholders, The Board of CytoMed wishes you a healthy and prosperous Year of the Snake. The snake's ability to shed its skin is often compared to rebirth and renewal, representing adaptability and growth in Chinese mythology. The snake's calm and quiet nature also embodi

      2/6/25 7:20:39 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytoMed Therapeutics signs Business & Research Collaboration Agreement with India's SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India

      SINGAPORE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic off-the-shelf immunotherapies for the treatment of various cancers, today announced that it has entered into a Business & Research Collaboration Agreement ("BRCA") with Mumbai-based SunAct Cancer Institute Private Limited ("SunAct"), a company incorporated in the Republic of India ("India"). The BRCA forms a collaborative effort between CytoMed and SunAct to explore and investigate the safety, tolerability, poten

      1/6/25 7:00:00 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GDTC
    Leadership Updates

    Live Leadership Updates

    See more
    • CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank

      SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has through its subsidiary, IPSC Depository Sdn Bhd, acquired the licence and certain assets of Cellsafe International Sdn Bhd (In Liquidation), a Malaysian cord blood bank. The acquisition includes (i) a cord blood banking licence issued by Malaysia's Ministry of Health, (ii) cryopreservation equipment with more than 12,000 cord blood units ("CBUs"

      10/3/24 7:00:00 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GDTC
    SEC Filings

    See more
    • SEC Form 6-K filed by CytoMed Therapeutics Limited

      6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)

      5/16/25 6:30:26 AM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CytoMed Therapeutics Limited

      6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)

      4/28/25 5:00:27 PM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by CytoMed Therapeutics Limited

      20-F - CytoMed Therapeutics Ltd (0001873093) (Filer)

      4/28/25 4:50:41 PM ET
      $GDTC
      Biotechnology: Pharmaceutical Preparations
      Health Care